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Abstract 
Over recent years, within the community of radiopharmaceutical sciences, there 
has been an increased incidence of incorrect usage of established scientific terms 
and conventions, and even the emergence of ‘self-invented’ terms. In order to 
address these concerns, an international Working Group on ‘Nomenclature in 
Radiopharmaceutical Chemistry and related areas’ was established in 2015 to 
achieve clarification of terms and to generate consensus on the utilisation of a 
standardised nomenclature pertinent to the field. 
Upon open consultation, the following consensus guidelines were agreed, which 
aim to: 
-  Provide a reference source for nomenclature good practice in the radiopharma-
ceutical sciences. 
-  Clarify the use of terms and rules concerning exclusively radiopharmaceutical 
terminology, i.e. nuclear- and radiochemical terms, symbols and expressions. 
-  Address gaps and inconsistencies in existing radiochemistry nomenclature rules. 
-  Provide source literature for further harmonisation beyond our immediate peer 
group (publishers, editors, IUPAC, pharmacopoeias, etc.). 
 
 
*authors for correspondence: h.h.coenen@fz-juelich.de; antony.gee@kcl.ac.uk 
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Introduction 
The primary function of nomenclature is to ensure that spoken or written 
scientific terms and concepts leave no ambiguity in their interpretation. The 
ultimate intent of generating consensus nomenclature is therefore to create 
common conventions for terms and definitions, enabling effective and 
unambiguous communication and understanding within a scientific community. 
In order to achieve these goals, the international natural science community 
agreed to abide by and adopt the use of SI-derived units (1960) [1] and IUPAC 
rules for chemistry (1921) [2] (SI - International System of Units; IUPAC - 
International Union of Pure and Applied Chemistry). As the field of 
radiopharmaceutical chemistry is part of this wider community, it also behoves us 
to adopt these conventions: to ignore this would be impractical. 
 
Over recent years, within the community of radiopharmaceutical sciences, there 
has been an increased incidence of incorrect usage of established scientific terms 
and conventions, and even the emergence of ‘self-invented’ terms. In order to 
address these concerns, in 2015 the 'Drug Development Committee' (DDC) of the 
'European Association of Nuclear Medicine' (EANM) established an international 
Working Group on ‘Nomenclature in Radiopharmaceutical Chemistry and related 
areas’ (H.H. Coenen, chair; A.D. Gee, co-chair). The scope of the Working Group 
was to achieve clarification of terms and to generate consensus on the utilisation 
of a standardised nomenclature pertinent to the field of radiopharmaceutical 
sciences. The members were selected on the basis of their scientific good standing 
and active engagement with relevant scientific societies, e.g., EANM, ‘Society of 
Radiopharmaceutical Sciences’ (SRS), ‘Society of Nuclear Medicine and Molecular 
Imaging’ (SNMMI), ‘International Association of Radiopharmacology’ (IAR) and 
respective national societies. 
 
After conducting a worldwide survey by questionnaire, a summary of the WG’s 
initial recommendations were produced. These were used as ‘guidelines to 
authors’ for the submission of abstracts for the 22nd International Symposium on 
Radiopharmaceutical Sciences (ISRS 2017). Other societies also responded 
positively to using this summary as guidelines for future abstract submissions at 
their meetings. In addition to the summary document, a full text was prepared by 
the WG and presented on the home page of the SRS in a wider context at the end of 
2016, requesting comments from peers in the field. 
 
Following a period of open consultation, in order to gain feedback on the proposed 
recommendations, all received comments and views were considered by the 
working group. The current guidelines, representing a consensus of the wider field 
of radiopharmaceutical sciences, were presented and approved at an open forum at 
the ISRS 2017 in Dresden (May, 2017). 
 
The consensus guidelines presented here aim to: 
- Provide a reference source for nomenclature good practice in the radiopharma-
ceutical sciences. 
- Clarify the use of terms and rules concerning exclusively radiopharmaceutical 
terminology, i.e. nuclear- and radiochemical terms, symbols and expressions. 
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- Address gaps and inconsistencies in existing radiochemistry nomenclature rules.  
- Provide source literature for further harmonisation beyond our immediate peer 
group (publishers, editors, IUPAC, pharmacopoeias, etc.). 
 
 
Scientific concepts, definitions, IUPAC rules and SI-derived units 
 
Below are summarised a number of terms (and descriptions thereof) of relevance 
to radiochemistry and related fields, which are described and already agreed upon 
by the wider scientific community, but are often used incorrectly in the literature. 
(for IUPAC see: [3] and for SI Units see: [4]). 
 
These are complemented by other terms, not described by international 
convention, but have been adopted within our field and have prompted discussion 
with a cross-section of experts within the field of nuclear and radio-chemistry in 
order to clarify and enhance the unambiguous communication of scientific 
findings and research results within the community. 
 
Measurement of radioactive decay 
 
The physical phenomenon of ‘radioactivity’ is a property of nuclides, which 
undergo spontaneous nuclear disintegration (radioactive decay). As such, 
'radioactivity' is not a measure or quantity. “Activity” and its SI derived unit, the 
“Becquerel”, are the agreed terms for the measure and quantity of radioactivity, 
respectively, [cf. 5, 6]. According to IUPAC [7] the definitions of these terms are: 
 
”Radioactivity” is defined as the property of certain nuclei to spontaneously 
fragment or rearrange, resulting in the emission of radiation. 
 
“Activity” is the quantitative measure of radioactivity: The number of nuclear 
decays, occurring in a given quantity of material over a certain time interval, 
divided by that time interval. 
 
“Becquerel” (Bq) is the agreed SI derived unit for the quantity of activity, equal 
to one disintegration per second. 
 
Pre-SI units (e.g. imperial units) (e.g. mCi, Ci) can also be used, but must be 
placed in parentheses after the stated SI units. (see Appendix B: Table) 
 
N.B.: In current practice, the term “radioactivity” is often used as a synonym for 
‘activity’ to describe the quantative measure of radioactive decay. This practice, 
although strictly speaking, incorrect according to IUPAC definition, can be helpful, 
as ‘activity’ is frequently used to describe other physical processes outside of a 
nuclear context, e.g. ‘enzyme activity’, ‘optical activity’ ‘structure activity 
relationship’, ‘activity coefficient’ etc. 
The use of the term “radioactivity” as a substitute for ‘activity’ therefore may 
actually add clarity in a cross-disciplinary context. This remains an outstanding 
issue for discussion with IUPAC, however, the use of “activity” is recommended 
until this is resolved. 
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Generally, the prefix “radio” indicates a context relating to the phenomenon of 
radioactivity, e.g. “radiochemistry”, or in combination with analytical methods, 
where it also denotes the measurement of radiation in addition to other 
spectroscopic signals, e.g., “radio-HPLC or radio-TLC”. 
 
Furthermore, the correct terms “radioactive” and “non-radioactive” must not be 
replaced by the often-used lab-jargon “hot” and “cold”, respectively, in formal 
public presentations, manuscripts or official documents. 
 
Specific activity (As) and molar activity (Am) 
According to SI convention, the term ‘specific’ refers to a physical property as a 
function of the mass of the material in question; e.g., the specific heat capacity is 
the heat capacity of an object per kg of mass. Since in chemistry the amount of 
material (mass) is most often denoted in moles, related chemical properties are 
indicated in ‘molar’ units; e.g., molar volume. Because of this possible source of 
confusion, the following terms are to be used correctly (see Appendix A): 
 
Specific activity - the measured activity per gram of compound; measured in 
Bq/g or GBq/mg etc.; symbol: As.  
 
Molar activity - the measured radioactivity per mole of compound; measured in 
Bq/mol or GBq/µmol, etc.; symbol: Am. 
 
Besides in the occasional situation, where the molecular weight cannot be 
determined, or in the context of radionuclide development (such as the activity of 
irradiated target material), the term ‘molar activity’ is to be used instead of the 
term ‘specific activity’. 
 
Due to radioactive decay, the measurement time for the specific activity or molar 
activity determination must be stated; e.g., ‘the specific activity was 50 GBq/mg’ or 
‘the molar activity was 50 GBq/µmol’ 2 h after the end of nuclide production, at 
the end of synthesis, at time of administration, etc.’ 
 
Apparent and effective specific and molar activity 
In cases where amounts of other material are present in a radiolabelled 
compound preparation, the measured specific or molar activity is lower than the 
true value. This often happens if non-labelled materials present in the synthesis 
mixture are not entirely removed from the labelled product during purification. 
 
Examples are precursor molecules (e.g., spiperone) or a complexing ligand (e.g., 
DOTA-TATE), which have not been fully removed during the final product 
purification (e.g., N-[methyl-11C]methylspiperone or [177Lu]Lu-DOTA-TATE) after 
methylation or complexation, respectively, but also any other chemically different 
impurity. 
 
In such cases, the terms ‘apparent specific activity’ and ‘apparent molar activity’ 
also take into account the amounts of the labelled and non-radiolabelled 
impurities (using moles, or weight, respectively). 
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An additional term used in this context is “effective specific or molar activity”. This 
addresses the chemically, biologically or pharmacologically ‘active’ fraction of 
radioactive and non-radioactive materials. The term is often used to consider 
other (unknown) material present in a sample prepared, competing with the 
labelled product in its chemical or biological reactions, for example a 
complexation process or the binding to a target protein. In this case, however, the 
“effectivity” must be determined by an additional analytical process (e.g., receptor 
or enzyme binding assay, etc.), since it is not simply described by the measured 
“activity per total amount (quantity or mass) of material”. 
 
The term “pseudo“ specific/molar activity must not be used, since the impurity 
has not been intentionally added. 
 
‘No-carrier-added’, ‘carrier-free’ and ‘carrier added’ (see also Appendix A) 
Since labelled compounds are generally mixtures of an isotopically unmodified 
compound and isotopically substituted compound(s), the non-quantitative terms 
“carrier-free” (c.f.), “no-carrier-added” (n.c.a.) and “carrier-added” (c.a.) are often 
used as a practical indication of specific/molar activity levels. These terms have 
already been adequately defined in 1981 by A.P. Wolf [8]) and intensively 
discussed by de Goeij and Bonardi [9] and in a thus far unpublished IUPAC draft 
from 2014 by Bonardi et al. [10]. 
 
It is advised, however, that, the term “carrier-free” should only be used in cases, 
where an analytical verification has proven this state, i.e., that the theoretical 
specific or molar activity (absence of all other than specified isotope) has been 
attained. 
 
Molar activity values approaching the theoretical values can be attained (e.g., 
technetium-99m in fresh eluates), and that extremely high values have been 
achieved with iodine-123, fluorine-18 and carbon-11 under certain conditions 
[11, 12, 13]). More recently, however, Eckelman et al. [14] and Lapi and Welch 
[15] emphasised, that the routinely used radionuclides (e.g., 11C, 18F, 99mTc, 123I, 
etc.) are never “carrier-free“. 
 
Thus, it is recommended to generally avoid the term “carrier-free” altogether. 
 
N.B.: While ‘carrier-free’ implies ‘no-carrier-added’, the reverse is not true! 
 
It has to be pointed out, that all measures, involving the determination of amounts 
of material (e.g., molar activity or radiochemical purity), should be accompanied 
by a clear description of the method of its detection. 
For example, “Compound X was obtained with an AM of 50 GBq/µmol in 98% 
radiochemical purity as determined by analytical HPLC, using UV absorption at λ = 
254 nm’.” 
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Radionuclide and radioisotope descriptors 
 
The enrichment of a chemical compound with an isotope (stable or radioactive) of 
one or more of the elements, of which it is constituted, is indicated by the symbol 
of the element (E), together with its mass number (A) (as a superscript in front), 
within square brackets, [AE], immediately preceding the compound’s name or 
chemical formula.  
Example: [2H,14C]benzene, or [2H,14C]C6H6,, represent the compound benzene, 
enriched or labelled, with stable deuterium and radioactive carbon-14, 
respectively. (see Appendix A). 
 
N.B.: The symbol for isotopic enrichment [AE] should be treated like a syllable, 
and thus only be hyphenated at the end of a line of text. 
 
If a symbol of an element is given in a chemical formula, or in combination with 
the name of a chemical compound, together with a mass number “AE”, but without 
square brackets, this indicates an isotopically substituted compound, having a 
composition such that all molecules of the compound only consist of the indicated 
(radio)nuclide (see Appendix A). This means that the theoretical specific or molar 
activity of the atom or compound is attained; i.e., it is strictly ‘carrier-free’, a state 
rarely achieved in practice (see ‘specific/molar activity’ above). 
 
Examples of correct and incorrect descriptions of isotopically labelled compounds: 
 
L-[13N]alanine or (S)-[13N]alanine are correct. 
[13N]L-alanine, L-13N-alanine, (S)-[13N]-alanine or L-[13N]-alanine are incorrect.  
More detailed rules for designating labelling positions (e.g., L-[methyl-11C]-
methionine or L-[carboxyl-11C]methionine), are described in a IUPAC document 
[7]. 
 
In the case of “fluorobenzene” labelled with fluorine-18: 
[18F]fluorobenzene is correct, while 
[18F]benzene is incorrect, since benzene does not contain a fluorine atom. 
Likewise, for technetium-III, forming a 1:1 complex with DTPA: 
[99mTc]TcDTPA2- is correct, while [99mTc]DTPA2- or 99mTc-DTPA2- are incorrect, 
since the chelator itself does not contain a technetium atom. 
 
According to these conventions, isotope symbols in square brackets in 
combination with nouns or verbs are meaningless and are to be avoided in a 
published chemical text or presentation. Instead, the element symbol together 
with the mass number must be used without any brackets. There is no 
contradiction or likelihood of confusion with the indication of a carrier-free state 
(see above), since nouns and verbs cannot be enriched or labelled with the 
indicated isotope. 
 
Consequently, for example [11C]compound, [125I]-substitution, [18F]-derivative and 
[68Ga]conjugate, are incorrect terms, since these nouns are not names of “chemical 
compounds”. These words should instead read as follows: 11C-compound, 125I-
substitution, 18F-derivative and 68Ga-conjugate (note: with hyphen!), or 
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preferably: 11C-labelled compound, substitution with iodine-125, 18F-tagged 
derivative, and 68Ga-labelled conjugate. Analogously, 68Ga-complex of a chelator, 
111In-chelate, 124I-iodinated antibody, or 99mTc-labelled conjugate are to be used. 
 
Equally, terms commonly found in literature such as [11C]labelling, [64Cu]-
labelling, or [18F]-(radio)fluorination are erroneous, because ‘labelling’ and 
‘radiofluorination’ are verbs and nouns and of course do not contain “chemical 
elements”. These expressions should instead read: 11C-labelling, 64Cu-labelling and 
18F-fluorination, while the prefix ‘radio’ is redundant here. 
 
Correspondingly, e.g., fluorine-18, technetium-99m, etc., should be used, rather 
than “18F” and “99mTc” (at least not without definition) as this would, strictly 
speaking, infer a carrier-free status for the radionuclide (see above). Generally, 
terms such as 18F, F18, F-18, or 99mTc, Tc99m, Tc-99m must not be used. 
 
Likewise, “76Br-“ (the bromine-76 anion) is more accurately described in texts by 
the terms [76Br ]bromide ion or [76Br ]Br-, and by analogy, [177Lu]Lu3+ is correct for 
the description of the [177Lu]lutetium cation rather than “177Lu3+”. 
 
N.B.: It is understood, however, that when used in chemical formulae, nuclide 
symbols or those of their ions are given without square brackets, and the latter 
can also be left out in graphical reaction schemes. 
 
These rules apply equally to organic, inorganic and organometallic compounds 
labelled with metallic radionuclides, and for complexes, they follow the same 
conventions as given above for covalently labelled compounds, e.g., [223Ra]RaCl2, 
[99mTc]NaTcO4, [99mTc]Tc-MDP, and [99mTc]Tc-MIBI. Examples of radiometal-
labelled conjugates are: “[68Ga]Ga-chelator-Z” (where “Z” is a place holder for a 
molecule to which the [metal(ligand)n] complex is attached to, e.g., a peptide or 
antibody such as in [68Ga]Ga-DOTA-TATE and [89Zr]Zr-DFO-trastuzumab. 
 
It should be mentioned that square brackets are of course also used to denote 
metal complexes, and care should be taken to avoid confusion (see also IUPAC 
recommendations ‘Nomenclature of Inorganic Chemistry’ [16]). 
Illustrative examples include [99mTc][Tc(CO)3(OH2)3]+, [111In][In(DTPA)]2-, 
[111In][In(oxyquinoline)3] ([111In]In-oxine), or [64Cu][Cu(ATSM)]. 
 
The terms ‘(radio)isotope’ and ‘(radio)nuclide’ are often used incorrectly in texts, 
e.g., erroneously inferring that “isotope” means “radioactive nuclide” or even 
“labelled compound”. 
 
N.B.: All (radio)isotopes are (radio)nuclides, while the reverse is not true! 
For example, both the nuclear reactions 176Yb(n,γ)177Yb (induced by thermal 
neutrons) and 124Xe(p,2n)123Cs (induced by charged particles) produce 
radionuclides, but only the first one leads to a radioisotope of the starting 
material. 
 
For the sake of clarification, the definition of these terms are repeated below: 
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- ‘Nuclide’ indicates an atom, characterised by its numbers of protons 
(atomic number, identifying its elemental nature) and of nucleons 
(indicating its mass). There are isobaric, isotonic, isodiapheric, and isotopic 
nuclides (see chart of the nuclides), which can be stable or radioactive, e.g., 
1H and 2H are stable, 3H is radioactive. 
- ‘Isotopes’ are nuclides of the same element (same proton number, i.e., 
atomic number), but having different numbers of neutrons (hence different 
atomic mass). Isotopic nuclides of different energy state are called isomeric 
nuclides, isomeric isotopes or isomers, such as technetium-99g and -99m. 
- ‘Isobars’ are nuclides with the same mass number, such as ruthenium-100, 
technetium-100, molybdenum-100, etc. 
- ‘Isotones’ are nuclides with the same number of neutrons, but different 
numbers of protons, such as hydrogen-2 (deuterium) and helium-3, or 
lithium-8, beryllium-9, boron-10, carbon-11, nitrogen-12 and oxygen-13. 
- ‘Isodiapheres’ are nuclides with the same difference of neutrons and 
protons, such as boron-10, carbon-12, nitrogen-14, oxygen-16, fluorine-18, 
neon-20, etc. (difference: zero), or titanium-49, vanadium-51, chromium-
53, manganese-55, iron-57, etc. (difference: five excess neutrons). 
(N.B.: These terms are also defined in the IUPAC Gold Book [7].) 
 
 
Radiochemical yield (RCY) 
 
Prior to a discussion of radiochemical yields, two facts should be considered: 
- Synthetic chemistry is the science of combining elements and molecules to 
form compounds in proportion to their components; i.e., in relation to their 
masses. Since it is the number of atoms/molecules that are generally 
referred to, amounts of materials are usually expressed in moles. 
(Example: 1 mole of carbon is combusted with 1 mole of oxygen gas to form 
1 mole of carbon dioxide; C + O2 -> CO2.) 
- Radiochemistry is the chemistry of radioactive materials (elements, atoms, 
molecules). With the exception of the field of ‘hot-atom-chemistry’, the 
standard laws and conventions of chemistry still apply, with the exception 
of accounting for radioactive decay. 
 
The correction for the decay of two (or more) radioactive samples to an identical 
point in time enables the law of relative masses to be employed; i.e., the 
application of established chemistry concepts, definitions and terms. 
 
‘Radiochemical yield’, calculated using decay-corrected radioactivity values for 
products and starting compounds, is identical to the concept of ‘chemical yield’. 
Logically, the reference time for correction of decay must be identical to describe a 
particular reaction, irrespective of whether it is chosen to be the end of the radio-
nuclide production, the end of bombardment, the start of synthesis, the end of 
synthesis, or any other convenient reference time point. 
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Definition of radiochemical yield (RCY) 
Radiochemical yield is the amount of activity in the product expressed as the 
percentage (%) of starting activity used in the considered process (e.g., synthesis, 
separation, etc.). The quantity of both must relate to the same radionuclide 
and be decay corrected to the same point in time before the calculation is 
made (see also Appendix A). 
It should be understood, that under this definition, the radiochemical yield is 
only related to the considered radionuclide, and it does not include compounds 
labelled with all radionuclides that may undergo the same reaction as the 
radionuclide of interest (e.g., Ge-68 in Ga-68 preparations). 
 
N.B.: Sometimes the amount of activity produced at the end of a nuclide 
production cannot be (or is not) determined, for example with gaseous 
compounds such as [11C]CO. However, it is recommended to measure the activity 
of resultant product or to determine the ‘trapping efficiency’ of the labelled 
starting material and use this to correct the RCY calculation. 
 
If it is accepted that radiochemical yields are always decay corrected (as is 
general convention in the wider nuclear and radiochemistry fields), it makes 
‘newly created’ terms to describe yields with radioactive materials superfluous. 
However, it enables an approach that is consistent with mainstream chemistry 
nomenclature, and it simplifies the understanding of our scientific findings and 
concepts within and outside the field of radiochemistry. 
Furthermore, it is good practise to report, if the radiochemical yield refers to an 
isolated or non-isolated product. 
 
Consider the following example. “The (radio)synthesis of compound Y”: 
The first step of reaction of A and B formed compound C, which was converted 
into D, oxidised to E and finally hydrolysed to product Y and then isolated by 
preparative HPLC. 
 
Description of chemical yields: The overall yield of product “Y” was 40 %. While the 
yield of C after the first step was 90 %, the yield of the conversion of C to D 
amounted only to 50 %; but the yield of oxidation and hydrolysis were almost 
quantitative. 
Description of radiochemical yields: The radiochemical yield of product “Y” was 
40 %. While the radiochemical yield of C after the first step was 90 %, the 
radiochemical yield of the conversion to D amounted only to 50 %; but the 
radiochemical yield of oxidation and hydrolysis were almost quantitative. 
 
If it is understood that radiochemical yield is identical to chemical yield, the 
sentences are identical and easily comprehended. If non-decay corrected yields 
were used, the ‘yields’ would be totally different to the standard chemical 
description of yields. 
 
By comparison, colloquial terms for “radio-yield” found in literature are neither 
necessary nor helpful: e.g., expressions such as ‘radiochemical conversion’, 
‘analytical radiochemical yield’, ‘radio-HPLC yield’ must not be used as a surrogate 
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for the accepted terms ‘radiochemical yield’ or ‘radiochemical purity’. If these 
terms were to be used, the previous example would be even more nonsensical. 
Also, a term such as ‘radiochemical conversion yield’ might give the impression 
that there is a nuclear change. Furthermore, other expressions such as 
‘radioincorporation’, ‘radio-oxidation’, ‘radiohydrolytic’ yield etc. would have the 
same justification. 
Equally, ‘analytical radiochemical yield’, ‘radio-HPLC yield’ should not be used as a 
surrogate for the accepted term radiochemical purity (RCP). 
 
The following are examples of good practice when describing radiochemical 
yields: 
‘The radiochemical yield of “Y” was 67 % (based on HPLC analysis of the crude 
product).” 
“The radiochemical yield* of “Y” was 67 %“, with the following as a footnote: 
*”determined by radio-HPLC analysis of the crude product”, or 
*”non-isolated, estimated by radio-HPLC”, 
or, in the general experimental section: “All radiochemical yields were determined 
by radio-HPLC analysis of the crude product, unless stated otherwise.”, 
or alternatively use: ‘The radiochemical purity of the crude product was 67 %.”, 
or: “The radiochemical yield of “Y” determined from an aliquot of the reaction 
solution amounted to 67 %.”, 
or: “The radiochemical yield of crude “Y“ was 67% based on the amount of activity 
eluted from the HPLC column”. 
 
Expressions such as ‘conversion’ or ‘incorporation’, however, may be used in a 
semantic sense and are indispensable in context of mechanistic discussions to 
avoid over-repetition of the same phrase in a text. For example: “The ‘conversion’ 
(or ‘incorporation’) proceeded with 50 % yield. Here it is clear from the context, 
that the radiochemical yield of the conversion or incorporation is intended. In this 
case, the prefix “radio” is to be avoided. 
 
 
Definition of activity yield (AY) 
Activity yield is the amount of radioactive product expressed in Bq (MBq, GBq), 
which is obtained from a starting amount of activity (e.g., produced from a 
cyclotron) and is not corrected for decay. 
 
This term is useful, or necessary to indicate the amount of radioactive product 
obtained from a starting amount of radioactivity. If this is expressed as a “non-
decay-corrected radiochemical yield” in %, it is significantly dependent on losses 
due to the technical manipulations used, and on their duration, in addition to the 
yield of the labelling reaction. 
 
Thus, if an “activity yield” is stated, e.g., to demonstrate the (economic) efficiency 
of a production process, the time required for all production steps should be 
carefully described in order to make results comparable! A rigorous scientific 
report or publication will indicate the length of reaction times used in addition to 
the time required for other technical manipulations. Only in this case, can starting 
activity levels be calculated from reported activity yields. 
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In an experimental section it should also state, if a yield is estimated using the 
measured radioactivity of the isolated product, or if it was estimated, for example, 
by HPLC analysis of a sample of the crude product. 
 
It is further recommended to specify how radioactivity, specific activity, etc. are 
analysed and measured; e.g., determined by HPLC. Although normally reported in 
the experimental section of publications, it may also be useful to include these 
clarifications in footnotes on slides and electronic presentations. 
 
 
Definitions of purity 
 
Chemical purity 
Chemical purity is the absence of other chemical compounds/species. 
(N.B.: 1. Chemically pure samples may contain isotopically labelled material! 
2. In the context of radiotracers, if chemical purity is described as ratio of the mass 
of carrier to the mass of other impurities this leads to a nonsensical result, i.e., that 
as the level of carrier decreases (and molar activity increases) the chemical purity 
would decrease! It is strongly discouraged, to report chemical purity in this 
manner. Furthermore, the determination of the chemical purity of 
radiopharmaceutical preparations containing ‘unknown materials’, using HPLC 
and UV detection, is a non-quantitative assessment. This issue requires careful 
consideration and further discussion. For further reading, see a compilation of 
criteria for quality assurance and control for radiopharmaceuticals in the chapter 
by G.-J. Meyer et al. of the monograph by Stöcklin and Pike [17]. 
 
Radiochemical purity 
Radiochemical purity is the absence of other radiochemical compounds/species. 
(N.B.: Radiochemically pure samples may contain other non-radioactive 
chemicals.) 
 
Radionuclidic purity 
Radionuclidic purity is the absence of other radionuclides. 
 
Radioisotopic purity 
Radioisotopic purity is the absence of other radioisotopes. This refers to 
radioisotopes of the same element, but not to radionuclides of other elements!  
 
N.B.: Here the ‘property’ of all these purities are defined. In practice, the ‘degree 
of purity’, i.e. its measure, is expressed as a percentage or fraction. For example, 
the ‘radionuclidic purity’ is given as the percentage of the activity of the radio-
nuclide with respect to the total activity of all radionuclides in the material. 
 
Examples: 
i) If a sample of acetyl-salicylic acid consists of a mixture of 11C-carbonyl 
labelled autologous compounds  (some labelled in the acetyl- position 
and some in the benzoyl-position), this material is chemically, 
radionuclidically, and radioisotopically pure, but not radiochemically. 
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ii) Iodine-123 labelled para-iodo-bromo-benzene is chemically and 
radioisotopically pure (i.e., containing no other radioiodine isotopes), but it 
may accidentally also contain bromine-77. This compound would neither be 
radionuclidically nor radiochemically pure. 
 
 
Physical units 
 
Attention must be paid to the correct use of physical units, such as using the correct 
term for a given unit (see above molar activity for Bq/mole). 
 
For example, in figures, such as radio-chromatograms, the y-axis indicating activity 
might generally be denoted by “Activity (arbitrary units)”, since quantities are generally 
not exactly measured. 
 
Another example that is frequently cited incorrectly in reports on nuclide production, is 
the erroneous use of “MBq/µAh” to represent the amount of activity produced per µA 
beam current during a 1-hour irradiation, unless this is clearly stated (or the exact time 
of bombardment is indicated). In fact, the yield of activity should actually relate to the 
activity produced per current or per number of charged particles applied. 
Thus, it is strongly encouraged to report either physical yields in units activity per 
charge (Becquerel per Coulomb, MBq/C) or saturation yields as activity per current 
(Becquerel per Ampere, MBq/µA), since all relevant information can be calculated from 
these parameters. 
 
This issue has been discussed for many years. In some instances, ‘measures’ of produced 
activity, using alternative units, may also be justified. If this is the case, however, 
definitions must be properly given. Such terms and their utility are explained in an IAEA 
document [18]. The topic was also recently dealt with in detail by Otuka and Takacs 
[19]. 
 
 
Summary and outlook 
 
One only has to read, for example, a few lines of one of the works of Shakespeare to 
appreciate that language always changes with the passing of time. This is also true for 
the language of science. The advancement and refinement of concepts, new scientific 
findings and developments necessitate the creative extension and adaptation or 
revision of existing terminology. Scientific communication with its sublime goal for 
exactness and precision also requires international standardisation to ensure 
unambiguous description and dissemination of findings. The frequent revisions of the 
‘so-called’ IUPAC ‘colour books’ on chemical nomenclature are an eloquent testimonial 
to the continued development of scientific language in the chemical sciences. 50 years 
of rapid advancements in the field of radiopharmaceutical science, have also produced 
a plethora of new terms and conventions necessitating the review and international 
harmonisation of the nomenclature discussed within this article. A comparison with an 
earlier guideline for authors (and editors) is worth reading, as it discusses also 
additional relevant items and provides a compilation of physical units [20]. 
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The urgency and timeliness of the current initiative was affirmed by the considerable 
amount of positive feedback from our colleagues in supporting the compilation of the 
guidelines, and the expeditious unanimity reached upon worldwide consultation. 
Nevertheless, the assembled consensus guidelines should be regarded as exemplars of 
‘best practice’, rather than strict rules or laws “written in stone”. The widespread 
adoption of these guidelines will ultimately be the arbiter of their utility and acceptance 
within the community. This will include their congruity with nomenclature rules from 
other areas of chemistry, not dealing with radioactivity, which are not the subject of the 
current initiative. To this end, it is anticipated that further revisions of these guidelines 
will be necessary at some point in the future. However, the resonance generated during 
the consultation phase and the broad interest received from journal editors already 
indicate this as a timely and worthwhile initiative. 
As pointed out above, existing international conventions are the basis of agreed 
nomenclature rules. Nevertheless, it is reasonable to anticipate future revisions aiming 
to aid clarity in scientific communication and in response to new findings and concepts. 
Although we generally recommended adhering to the current IUPAC guidance, several 
discrepancies and differences in IUPAC rules have been highlighted in this manuscript, 
for which we recommend alternatives agreed by consensus. These include for example: 
the definition of radiochemical yield (decay corrected vs. uncorrected); definitions of 
purity; and symbols for specific and molar activity (IUPAC nomenclature is not self-
consistent). Furthermore, the wider community judged that ‘activity’ is too general an 
expression to unambiguously describe the measure of radioactivity, and should be an 
issue for further discussion. Until this is resolved, we recommend retaining the use of 
‘activity’, unless the context dictates that ambiguity may result. Further examination and 
discussion of these differences with IUPAC is in progress, in anticipation of a revision of 
some radiochemistry-relevant terms in the near future. 
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Appendix A 
 
Some Definitions from IUPAC Nomenclature Documents 
 
For completeness and comparison, several extracts of IUPAC Books are given: 
The convention for naming radioactive matter is concisely described in 
‘Nomenclature of Inorganic Chemistry, IUPAC Recommendations 2005’: 
(www.iupac.org/fileadmin/user_upload/databases/Red_Book_2005.pdf). 
A more detailed treatment of these conventions are provided in chapter II-2 of 
‘Nomenclature of Inorganic Chemistry II, IUPAC Recommendations 2000’ (Red 
Book II), and in the IUPAC Nomenclature of Organic Chemistry (Blue Book) 
prepared by Advanced Chemistry Development; found on the ACD website: 
http://acdlabs.com/iupac/nomenclature. The corresponding ‘Compendium on 
Analytical Nomenclature’ (Orange Book) is under revision. The 1988 online 
version is found via: https://www.iupac.org/home/publications/technical-
reports/guidelines-for-drafting-reports/references.html. 
 
As mentioned above, a new draft IUPAC document on “Terminology on carrier, 
specific activity, and purities in nuclear and radio-chemistry, radio-analytical and 
radiopharmaceutical chemistry” by Bonardi et al. [10] is currently under 
discussion. 
 
 
Indication of mass, charge and atomic number using indexes (Red Book) 
The mass, charge and atomic number of a nuclide are indicated by means of three 
indexes (subscripts and superscripts) placed around the element symbol.  
The positions are occupied as follows: 
- left upper index mass number 
- left lower index atomic number 
- right upper index charge 
A charge placed on an atom of symbol A is indicated as An+ or An-, not as A+n or A-n. 
For example: Sଵ଺ଷଶ 2+ represents a doubly ionised sulphur atom of atomic number 16 
and mass number 32. 
 
Hydrogen is an exception in that the three isotopes 1H, 2H and 3H can have the 
alternative names protium, deuterium and tritium, respectively, and the symbols D 
and T may be used for deuterium and tritium. However, 2H and 3H are preferred, 
because D and T can disturb the alphabetical ordering in formulae. These names 
give rise to the names proton, deuteron, triton for the cations 1H+, 2H+ and 3H+, 
respectively. Because the word ‘proton’ is often used in contradictory senses, i.e., for 
isotopically pure 1H+ ions on the one hand, and for the naturally occurring 
undifferentiated isotope mixture on the other, it is recommended that the 
undifferentiated mixture be designated by the name hydron, derived from hydrogen. 
 
It has to be pointed out, that the lower-case characters p, d, t and the symbol α are 
also valid descriptors for the ions of hydrogen and helium, respectively, and are 
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generally used when describing nuclear reactions, e.g., 14N(p, α)11C, or isotopically 
substituted solvents, such as DMSO-d6 in NMR-spectroscopy. 
Specifically and selectively labelled compounds (Red Book) 
An isotopically substituted compound has a composition such that all the 
molecules of the compound have only the indicated nuclide(s) at each designated 
position. The substituted nuclides are indicated by insertion of the mass numbers as 
left superscripts preceding the appropriate atom symbols in the normal formula. 
 
An isotopically labelled compound may be considered formally as a mixture of 
an isotopically unmodified compound and one or more analogous isotopically 
substituted compounds.  
An isotopically labelled compound is called a specifically labelled compound 
when a unique isotopically substituted compound is added formally to the 
analogous isotopically unmodified compound. 
A selectively labelled compound may be considered as a mixture of specifically 
labelled compounds. 
 
Specific activity and molar activity (Orange Book proposal) 
Specific Activity: ’The activity (A) of a specified radionuclide, or of a mixture of 
radioisotopes, in an amount of substance divided by the mass (m) of the total 
number of atoms present in it. Symbol: a = A/m. 
Molar Activity: ‘For a specified isotope, the activity (A) of a molecule 
incorporating the radionuclide divided by its molecular weight (M) expressed in 
moles. Symbol: Am = A/M.’ 
 
Status of carrier (Orange Book proposal): 
Carrier-free: ‘A radioactive nuclide, which is measurable free from stable isotopes 
of the corresponding element.’ 
No-carrier-added: ‘A preparation of radioactive nuclide which is essentially free 
from stable isotopes of the corresponding element. 
 
Radiochemical Yield (Gold Book and Orange Book proposal) 
‘The ratio of the activity of a specified radionuclide of a specified element after its 
radiochemical separation and its activity originally present in the substance 
undergoing the radiochemical separation.’ 
 
Radiochemical purity and radioactive purity (Orange Book proposal) 
Radiochemical purity: ‘Ratio of the activity of a radionuclide in a stated chemical 
species in a material over the total activity of all species containing that 
radionuclide in this material.’  
Radioactive Purity: ‘Ratio of the activity of a stated radionuclide over the total 
activity of all radionuclides present in a material.’ 
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Appendix B 
 
Definitions and Units of Radiological Measures 
 
 
Measure Definition SI-Unit* Older Unit Conversion Factor 
Activity 
(Decay rate) 
Number of radioactive  
disintegrations per time 
Becquerel 
1 Bq = 1 s-1 
Curie 
1 Ci = 3.7 . 1010 s-1 
1 Ci = 3.7 . 1010  Bq 
1 Bq = 2.7 . 10-11 Ci 
Energy  
dose 
Total absorbed radiation  
energy per mass 
Gray 
1 Gy = 1 J/kg 
Rad 
1 rad = 10-2 J/kg 
1 rad = 10-2 Gy 
1 Gy = 100 rad 
Equivalent  
dose 
Energy dose . quality  
factor of type of radiation 
Sievert 
1 Sv = 1 J/kg 
Rem 
1 rem = 10-2 J/kg 
1 rem = 10-2 Sv 
1 Sv = 100 rem 
Ion  
dose 
Electrical charge of ions  
produced in 1 kg air by  
radiation 
Coulomb/kg Röntgen 
R 
1 R = 2.58 . 10-4 C/kg 
1 C/kg = 3.876 . 103 R 
 
*SI Units = International System of Units 
